Detalhe da pesquisa
1.
Durability of Antibody Response and Frequency of SARS-CoV-2 Infection 6 Months after COVID-19 Vaccination in Healthcare Workers.
Emerg Infect Dis
; 28(4): 828-832, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35203111
2.
Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) study: an observational cohort study of SARS-CoV-2 infection and vaccination in healthcare workers.
BMC Infect Dis
; 21(1): 544, 2021 Jun 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34107889
3.
Natural killer cells and BNT162b2 mRNA vaccine reactogenicity and durability.
Front Immunol
; 14: 1225025, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37711632
4.
Adverse Effects and Antibody Titers in Response to the BNT162b2 mRNA COVID-19 Vaccine in a Prospective Study of Healthcare Workers.
Open Forum Infect Dis
; 9(1): ofab575, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-35047649
5.
Cellular interferon-gamma and interleukin-2 responses to SARS-CoV-2 structural proteins are broader and higher in those vaccinated after SARS-CoV-2 infection compared to vaccinees without prior SARS-CoV-2 infection.
PLoS One
; 17(10): e0276241, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36251675
6.
Prospective Assessment of Symptoms to Evaluate Asymptomatic SARS-CoV-2 Infections in a Cohort of Health Care Workers.
Open Forum Infect Dis
; 9(3): ofac030, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35198647
7.
Adverse effects and antibody titers in response to the BNT162b2 mRNA COVID-19 vaccine in a prospective study of healthcare workers.
medRxiv
; 2021 Jul 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34230937
8.
A three-antigen Plasmodium falciparum DNA prime-Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults.
PLoS One
; 16(9): e0256980, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34495988
9.
IMRAS-A clinical trial of mosquito-bite immunization with live, radiation-attenuated P. falciparum sporozoites: Impact of immunization parameters on protective efficacy and generation of a repository of immunologic reagents.
PLoS One
; 15(6): e0233840, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32555601
10.
A systematic review of safety data reporting in clinical trials of vaccines against malaria, tuberculosis, and human immunodeficiency virus.
Vaccine
; 31(35): 3628-35, 2013 Aug 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-23395586
11.
Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection.
Hum Vaccin Immunother
; 9(10): 2165-77, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23899517
12.
DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity.
PLoS One
; 8(2): e55571, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23457473
13.
Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component.
PLoS One
; 6(10): e25868, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-22003411